Evotec 9M 2026 operating loss more than doubles to EUR 254.78 million
Bitget2026/11/05 06:30- Evotec’s net loss widened 65% year-over-year to EUR 195.3 million in the first nine months of 2026, partly due to higher restructuring costs.
- Revenue fell 13% to EUR 465 million, with lower revenue recognition across all Discovery & Preclinical Development businesses.
- Operating cash outflow more than doubled to EUR 155 million, primarily reflecting operating performance and related working-capital changes.
- The Horizon transformation ran slightly ahead of schedule, supporting plans to realize some targeted annual savings earlier.
- Full-year 2026 revenue guidance remained unchanged at EUR 570 million to EUR 610 million.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Blackstone (BX.US) injects up to $1.5 billion, providing fresh ammunition for Pfizer (PFE.US) in the weight-loss drug race
Pfizer announced on Wednesday that it has reached an agreement with Blackstone to obtain up to $1.5 billions in funding to support the development of its experimental monthly obesity treatment drug.
Bernstein Downgrades Nvidia Rating and Target Price
Google (GOOGL.US) DeepMind launches AlphaGenome 2: Capable of decoding DNA cells with nearly double the mutation identification capacity
Google DeepMind has released its AI model AlphaGenome 2, which is trained on maps of over 100 millions of cells and has nearly double the ability of its predecessor in identifying gene expression variations.
Crypto prices
More
